Research Paper Volume 16, Issue 1 pp 928—947

Mechanism of lysine oxidase-like 1 promoting synovial inflammation mediating rheumatoid arthritis development

Jiawei Hu1, , Xuqiang Liu1, , Qiang Xu1, , Meisong Zhu1, , Song Wang1, , Kun Quan1, , Min Dai1, , Fengbo Mo1, , Haibo Zhan1, ,

  • 1 Department of Orthopedics, The 1st Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi Province 330006, China

Received: July 20, 2023       Accepted: December 1, 2023       Published: January 12, 2024      

https://doi.org/10.18632/aging.205429
How to Cite

Copyright: © 2024 Hu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory joint disease that causes great distress to patients and society. Early diagnosis is the key to the successful treatment of RA. The basement membrane, one of the oldest tissue structures, is localized under the epithelium. Its complex composition and rich biological functions have made it a focus of research in recent years, while basement membrane-associated genetic variants are involved in most human disease processes. The aim of this study is to find new diagnostic biomarkers for RA and explore their role and possible mechanism in rheumatoid arthritis. The GSE12021, GSE55235 and GSE55457 datasets were downloaded from the GEO database. Their fraction associated with basement membrane genes was analyzed and differentially expressed genes between the disease and normal groups were explored. We identified two basement membrane-associated genes, lysine oxidase-like 1 (LOXL1) and discoid peptide receptor 2 (DDR2). Focusing on the more interesting LOXL1, we found that LOXL1 expression was significantly elevated in the synovium of patients with rheumatoid arthritis, and LOXL1 mRNA and protein levels were elevated in tumor necrosis factor α-stimulated human synovial sarcoma cells (SW982). And LOXL1 knockdown inhibited tumor necrosis factor α-induced inhibition in SW982 cells expression of inducible nitric oxide synthase (INOS), cyclooxygenase-2 (COX2), and interleukin-6 (IL-6). Interestingly, knockdown of LOXL1 inhibited the phosphorylation of PI3K and AKT. In summary, LOXL1 may become a novel diagnostic gene for RA, and knockdown of LoxL1 may inhibit synovial inflammation by affecting PI3K/AKT pathway.

Abbreviations

RA: Rheumatoid arthritis; OA: osteoarthritis; LOXL1: lysine oxidase-like 1; DDR2: discoid peptide receptor 2; TNF-α: tumor necrosis factor α; INOS: inducible nitric oxide synthase; COX2: cyclooxygenase-2; IL-6: interleukin-6; BMs: Basement membranes; GO: Gene Ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; SVMs: Support Vector Machines; RFE: recursive feature elimination; ECM: extracellular matrix; MMPs: matrix metalloproteinases; LOX: Lysyl oxidase; PBS: Phosphate Buffer Saline: FBS: fetal bovine serum; PVDF: polyvinylidene fluoride; CCK-8: cell counting kit-8; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; qPCR: quantitative real-time polymerase chain reaction; EDTA: ethylenediaminetetraacetic acid; H&E: hematoxylin and eosin.